Ex-Pharmacyclics team raises $33.5M for checkpoint drug

Richard Miller

Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals. Dow Jones reports on the Burlingame, CA-based biotech's plans after its $33.5 million venture round, which was led by OrbiMed. Central to its future is a checkpoint inhibitor, which Miller says targets a new and undisclosed protein. Miller created the company with the help of another ex-Pharmacyclics exec, Joseph Buggy, and OrbiMed Private Equity Partner Peter Thompson. A Phase Ib study is expected to get started in early 2016. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.